clarivate plc - CLVT
CLVT
Close Chg Chg %
3.41 0.09 2.64%
Closed Market
3.50
+0.09 (2.64%)
Volume: 2.95M
Last Updated:
Dec 26, 2025, 3:59 PM EDT
Company Overview: clarivate plc - CLVT
CLVT Key Data
| Open $3.45 | Day Range 3.40 - 3.54 |
| 52 Week Range 3.04 - 5.74 | Market Cap $2.26B |
| Shares Outstanding 661.44M | Public Float 361.12M |
| Beta 1.52 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.57 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.48M |
CLVT Performance
| 1 Week | -2.29% | ||
| 1 Month | -9.31% | ||
| 3 Months | -7.59% | ||
| 1 Year | -33.40% | ||
| 5 Years | -88.67% |
CLVT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About clarivate plc - CLVT
Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.
CLVT At a Glance
Clarivate Plc
70 St. Mary Axe
London, Greater London EC3A 8BE
| Phone | 44-207-4334000 | Revenue | 2.56B | |
| Industry | Miscellaneous Commercial Services | Net Income | -636,700,000.00 | |
| Sector | Commercial Services | Employees | 12,000 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CLVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.378 |
| Price to Book Ratio | 0.683 |
| Price to Cash Flow Ratio | 5.62 |
| Enterprise Value to EBITDA | 8.148 |
| Enterprise Value to Sales | 3.059 |
| Total Debt to Enterprise Value | 0.587 |
CLVT Efficiency
| Revenue/Employee | 213,058.333 |
| Income Per Employee | -53,058.333 |
| Receivables Turnover | 3.203 |
| Total Asset Turnover | 0.211 |
CLVT Liquidity
| Current Ratio | 0.868 |
| Quick Ratio | 0.868 |
| Cash Ratio | 0.206 |
CLVT Profitability
| Gross Margin | 37.568 |
| Operating Margin | 9.109 |
| Pretax Margin | -21.661 |
| Net Margin | -24.903 |
| Return on Assets | -5.263 |
| Return on Equity | -11.44 |
| Return on Total Capital | -6.543 |
| Return on Invested Capital | -6.215 |
CLVT Capital Structure
| Total Debt to Total Equity | 89.366 |
| Total Debt to Total Capital | 47.192 |
| Total Debt to Total Assets | 39.969 |
| Long-Term Debt to Equity | 88.965 |
| Long-Term Debt to Total Capital | 46.98 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Clarivate Plc - CLVT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.88B | 2.66B | 2.63B | 2.56B | |
Sales Growth
| +49.67% | +41.71% | -1.17% | -2.74% | |
Cost of Goods Sold (COGS) incl D&A
| 1.16B | 1.66B | 1.61B | 1.60B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 537.82M | 710.50M | 708.30M | 727.00M | |
Depreciation
| 14.00M | 35.20M | 23.20M | 19.00M | |
Amortization of Intangibles
| 523.82M | 675.30M | 685.10M | 708.00M | |
COGS Growth
| +58.91% | +43.01% | -2.99% | -1.15% | |
Gross Income
| 712.98M | 995.30M | 1.01B | 960.50M | |
Gross Income Growth
| +36.69% | +39.60% | +1.89% | -5.29% | |
Gross Profit Margin
| +37.99% | +37.42% | +38.58% | +37.57% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 668.07M | 729.90M | 739.70M | 727.60M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 668.07M | 729.90M | 739.70M | 727.60M | |
SGA Growth
| +27.60% | +9.25% | +1.34% | -1.64% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 23.05M | 4.31B | 954.60M | 555.10M | |
EBIT after Unusual Expense
| 21.85M | (4.04B) | (680.20M) | (322.20M) | |
Non Operating Income/Expense
| (27.51M) | 324.80M | (38.60M) | 51.80M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 252.49M | 270.30M | 293.70M | 283.40M | |
Interest Expense Growth
| +120.73% | +7.05% | +8.66% | -3.51% | |
Gross Interest Expense
| 252.49M | 270.30M | 293.70M | 283.40M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (258.15M) | (3.99B) | (1.01B) | (553.80M) | |
Pretax Income Growth
| +17.83% | -1,445.26% | +74.62% | +45.30% | |
Pretax Margin
| -13.75% | -149.98% | -38.52% | -21.66% | |
Income Tax
| 12.30M | (28.90M) | (101.30M) | 82.90M | |
Income Tax - Current - Domestic
| 5.09M | 1.70M | (21.90M) | 58.90M | |
Income Tax - Current - Foreign
| 24.58M | 35.10M | (1.20M) | 2.30M | |
Income Tax - Deferred - Domestic
| 3.22M | (59.80M) | (77.80M) | 20.90M | |
Income Tax - Deferred - Foreign
| (20.59M) | (5.90M) | (400.00K) | 800.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (270.45M) | (3.96B) | (911.20M) | (636.70M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (270.45M) | (3.96B) | (911.20M) | (636.70M) | |
Net Income Growth
| +13.28% | -1,364.31% | +76.99% | +30.13% | |
Net Margin Growth
| -14.41% | -148.89% | -34.66% | -24.90% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (270.45M) | (3.96B) | (911.20M) | (636.70M) | |
Preferred Dividends
| 41.51M | 75.40M | 75.40M | 31.30M | |
Net Income Available to Common
| (311.96M) | (4.04B) | (986.60M) | (668.00M) | |
EPS (Basic)
| -0.4944 | -5.9689 | -1.469 | -0.9631 | |
EPS (Basic) Growth
| +32.05% | -1,107.30% | +75.39% | +34.44% | |
Basic Shares Outstanding
| 630.98M | 676.10M | 671.60M | 693.60M | |
EPS (Diluted)
| -0.6138 | -6.2381 | -1.469 | -0.9631 | |
EPS (Diluted) Growth
| +15.64% | -916.31% | +76.45% | +34.44% | |
Diluted Shares Outstanding
| 640.77M | 678.60M | 671.60M | 693.60M | |
EBITDA
| 582.72M | 975.90M | 982.70M | 959.90M | |
EBITDA Growth
| +93.48% | +67.47% | +0.70% | -2.32% | |
EBITDA Margin
| +31.05% | +36.69% | +37.38% | +37.54% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 4.85 | |
| Number of Ratings | 10 | Current Quarters Estimate | 0.166 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 0.662 | |
| Last Quarter’s Earnings | 0.18 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.73 | Next Fiscal Year Estimate | 0.676 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 9 |
| Mean Estimate | 0.17 | 0.14 | 0.66 | 0.68 |
| High Estimates | 0.18 | 0.15 | 0.68 | 0.74 |
| Low Estimate | 0.15 | 0.12 | 0.64 | 0.62 |
| Coefficient of Variance | 6.83 | 8.86 | 1.79 | 5.93 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 4 |
| OVERWEIGHT | 1 | 1 | 0 |
| HOLD | 5 | 6 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 2 | 1 | 1 |
| MEAN | Hold | Hold | Overweight |
SEC Filings for Clarivate Plc - CLVT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Clarivate Plc - CLVT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 17, 2025 | Michael James Angelakis Director | 49,750 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.03 per share | 200,492.50 |
| Mar 7, 2025 | William E. Graff EVP, Chief Information Officer | 393,514 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.15 per share | 1,633,083.10 |
| Mar 7, 2025 | James Gordon Samson President, IP | 1,128,973 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.15 per share | 4,685,237.95 |
| Mar 7, 2025 | James Gordon Samson President, IP | 1,133,938 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michael M. Easton Senior VP, Finance/CAO | 335,854 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.15 per share | 1,393,794.10 |
| Mar 7, 2025 | Michael M. Easton Senior VP, Finance/CAO | 339,916 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Jonathan M. Collins Executive Vice President/CFO | 693,760 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.15 per share | 2,879,104.00 |
| Mar 7, 2025 | Jonathan M. Collins Executive Vice President/CFO | 713,081 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | William E. Graff EVP, Chief Information Officer | 397,039 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendell E. Pritchett Director | 71,835 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.38 per share | 314,637.30 |
| Mar 6, 2025 | Saurabh Saha Director | 82,016 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.36 per share | 357,589.76 |
| Jan 6, 2025 | Richard W. Roedel Director | 107,971 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $5.08 per share | 548,492.68 |
| Jan 6, 2025 | Andrew M. Snyder Director | 103,157 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.08 per share | 524,037.56 |
| Jan 6, 2025 | Andrew M. Snyder Director | 107,414 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $5.08 per share | 545,663.12 |
| Jan 6, 2025 | Jane L. Okun Bomba Director | 162,628 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.08 per share | 826,150.24 |
| Jan 6, 2025 | Jane L. Okun Bomba Director | 162,945 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $5.08 per share | 827,760.60 |
| Jan 6, 2025 | Richard W. Roedel Director | 106,645 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.08 per share | 541,756.60 |
| Jan 6, 2025 | Richard W. Roedel Director | 107,714 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.08 per share | 547,187.12 |